Journal article
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer
J Tie, JD Cohen, K Lahouel, SN Lo, Y Wang, S Kosmider, R Wong, J Shapiro, M Lee, S Harris, A Khattak, M Burge, M Harris, J Lynam, L Nott, F Day, T Hayes, SA McLachlan, B Lee, J Ptak Show all
New England Journal of Medicine | Published : 2022
Abstract
BACKGROUND The role of adjuvant chemotherapy in stage II colon cancer continues to be debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor recurrence-free survival, whereas its absence predicts a low risk of recurrence. The benefit of adjuvant chemotherapy for ctDNA-positive patients is not well understood. METHODS We conducted a trial to assess whether a ctDNA-guided approach could reduce the use of adjuvant chemotherapy without compromising recurrence risk. Patients with stage II colon cancer were randomly assigned in a 2:1 ratio to have treatment decisions guided by either ctDNA results or standard clinicopathological features. For ctDNA-guided managemen..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
Supported by a grant (APP1085531) from the Australian National Health and Medical Research Council, a grant (APP1194970) from the Medical Research Future Fund, the Marcus Foundation, the Virginia and D.K. Ludwig Fund for Cancer Research, the Lustgarten Foundation, the Conrad R. Hilton Foundation, the Sol Goldman Charitable Trust, John Templeton Foundation, grants (CA62924, CA009071, GM136577, and CA06973) from the National Institutes of Health, and a Linda Williams Memorial Grant from the Eastern Health Research Foundation.